- Intranasal lipid nanocapsule delivery of Q-iP-DHA improved well-being, organisational skills and spatial memory in J20 transgenic mice.
- Q-iP-DHA treatment reduced hippocampal amyloid plaque burden and normalised RAGE expression, indicating amyloid and receptor modulation.
- The lipophenol lowered carbonyl stress and microglial activation, supporting anti-inflammatory, multitarget neuroprotective potential for Alzheimer's disease.
Drug Deliv Transl Res. 2026 May 6. doi: 10.1007/s13346-026-02142-5. Online ahead of print.
ABSTRACT
Oxidative and carbonyl stresses (COS), which damage brain cells through the accumulation of toxic reactive carbonyl species (RCS), are key players in the etiology of Alzheimer’s disease (AD). Our group developed lipophenols, i.e. COS-targeting hybrid molecules combining polyunsaturated fatty acids (PUFAs) and alkyl-(poly)phenols. Among them, quercetin-3-O-docosahexaenoate-7-O-isopropyl (Quercetin-3-O-DHA-7-O-iPr or “Q-iP-DHA”) afforded neuroprotection against acrolein-induced toxicity, reduced carbonyl stress, and lowered amyloid-beta secretion in neuroblastoma cells. To evaluate Q-iP-DHA in vivo, it was formulated into lipid nanocapsules (to allow solubilization) then administered intranasally to J20 transgenic mice, a model of AD. This approach was chosen to optimize blood-brain barrier (BBB) penetration. This delivery led to improvements in well-being, organizational skills and spatial memory. In addition, Q-iP-DHA treatment reduced hippocampal amyloid plaque numbers, normalized expression of the Receptor for Advanced Glycation End-products (RAGE), and decreased microglial activation, indicating anti-inflammatory effects. Overall, our preclinical findings suggest that intranasal administration of nanoformulated Q-iP-DHA may represent a promising multitarget therapeutic approach against AD.
PMID:42091792 | DOI:10.1007/s13346-026-02142-5
Share Evidence Blueprint
Save to Google Notes
Search Google Scholar
Save as PDF
⭐ My Revision List
